Aprea Therapeutics Inc Net Assets
Aprea Therapeutics Inc net assets. Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has net assets worth $38.47 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.29 Million) and total liabilities ($3.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Aprea Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.47 Million |
| % of Total Assets | 90.97% |
| Annual Growth Rate | N/A |
| 5-Year Change | -74.87% |
| 10-Year Change | N/A |
| Growth Volatility | 17.0 |
Net Assets of Aprea Therapeutics Inc (2007–2025)
Net assets of Aprea Therapeutics Inc from 2007 to 2025. This chart illustrates how Aprea Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Aprea Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Aprea Therapeutics Inc (2007–2025)
The table below shows the annual net assets of Aprea Therapeutics Inc from 2007 to 2025. For live market cap and overall valuation, see Aprea Therapeutics Inc (APRE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $12.44 Million | -35.56% |
| 2024-12-31 | $19.31 Million | +5.71% |
| 2023-12-31 | $18.26 Million | -28.78% |
| 2022-12-31 | $25.64 Million | -48.20% |
| 2021-12-31 | $49.51 Million | -36.03% |
| 2020-12-31 | $77.40 Million | -37.71% |
| 2019-12-31 | $124.24 Million | +341.55% |
| 2018-12-31 | $-51.44 Million | -43.82% |
| 2017-12-31 | $-35.77 Million | -1592.10% |
| 2007-12-31 | $-2.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aprea Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30647189600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Aprea Therapeutics Inc Net Assets Breakdown (December 2025)
Aprea Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.19K | 0.07% |
| Other Comprehensive Income | $-10.63 Million | -85.48% |
| Other Components | $356.71 Million | 2867.05% |
| Total Equity | $12.44 Million | 100.00% |
Aprea Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aprea Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EXPLOITS DISCOVERY CORP.
F:634
|
$6.49 Million |
|
Saxlund Group AB
ST:SAXG
|
$6.49 Million |
|
Xylo Technologies Ltd.
NASDAQ:XYLO
|
$6.49 Million |
|
Foresight Group Holdings Limited
LSE:FSG
|
$6.49 Million |
|
Hwa Tai Industries Bhd
KLSE:8478
|
$6.48 Million |
|
Innelec Multimedia
PA:ALINN
|
$6.48 Million |
|
Ambipar Emergency Response
NYSE MKT:AMBI
|
$6.48 Million |
|
In-Touch Survey Systems Ltd.
V:INX
|
$6.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aprea Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,307,455 to 12,441,682, a change of -6,865,773 (-35.6%).
- Net loss of 12,599,569 reduced equity.
- New share issuances of 5,047,606 increased equity.
- Other comprehensive income decreased equity by 7,335.
- Other factors increased equity by 693,525.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.60 Million | -101.27% |
| Share Issuances | $5.05 Million | +40.57% |
| Other Comprehensive Income | $-7.33K | -0.06% |
| Other Changes | $693.52K | +5.57% |
| Total Change | $- | -35.56% |
Book Value vs Market Value Analysis
This analysis compares Aprea Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.27x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-50.82 | $0.52 | x |
| 2018-12-31 | $-73.09 | $0.52 | x |
| 2019-12-31 | $123.64 | $0.52 | x |
| 2020-12-31 | $73.24 | $0.52 | x |
| 2021-12-31 | $46.51 | $0.52 | x |
| 2022-12-31 | $309.51 | $0.52 | x |
| 2023-12-31 | $5.05 | $0.52 | x |
| 2024-12-31 | $3.50 | $0.52 | x |
| 2025-12-31 | $1.90 | $0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aprea Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -101.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4409.16%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.28x
- Recent ROE (-101.27%) is below the historical average (-85.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -5193.06% | 0.22x | 0.00x | $-3.31 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.61 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.38 Million |
| 2019 | -22.58% | 0.00% | 0.00x | 1.08x | $-40.48 Million |
| 2020 | -69.66% | 0.00% | 0.00x | 1.20x | $-61.66 Million |
| 2021 | -73.80% | 0.00% | 0.00x | 1.15x | $-41.49 Million |
| 2022 | -439.34% | 0.00% | 0.00x | 1.18x | $-115.23 Million |
| 2023 | -78.22% | -2449.59% | 0.03x | 1.24x | $-16.11 Million |
| 2024 | -67.12% | -862.43% | 0.06x | 1.24x | $-14.89 Million |
| 2025 | -101.27% | -4409.16% | 0.02x | 1.28x | $-13.84 Million |
Industry Comparison
This section compares Aprea Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aprea Therapeutics Inc (APRE) | $38.47 Million | 0.00% | 0.10x | $6.48 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more